Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate considers expanding $25 insulin cap from state plan to portions of the commercial market
Summary
Senate Bill 2,370 would extend a $25 monthly cap on insulin and diabetic supplies, adopted as a PERS pilot, into parts of the regulated commercial market; proponents cited member savings and minimal premium impact in the PERS pilot while insurers and business groups warned mandates can raise overall premiums and urged alternative approaches.
Senate Bill 2,370 would expand a $25 monthly cap on insulin and certain diabetic supplies beyond the PERS pilot program to the stateregulated commercial market, sponsor Sen. Sean Cleary told the Senate Human Services Committee.
Cleary said the underlying PERS pilot (created by a prior session bill) showed member savings of roughly $80 per month per affected member and an estimated increase in premium on the PERS plan of about 0.14 percent. Rebecca Fricke, executive director of the Public Employees Retirement System, told the committee PERSactuarial analysis estimated continuing the cap for the upcoming biennium would increase premium by approximately 0.12 percent or roughly $1.0 million total (about $834,000 for state agencies and $160,000 for participating political subdivisions). PERS recommended continuation for its plan but did…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
